Gilead’s Yeztugo offers 6-month HIV protection and becomes the first PrEP injection approved for twice-yearly use.

WASHINGTON — (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated ...

On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...

It reduces transmissions by up to 96%, but now world governments and big-dollar funders will need to step in.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Health-care companies were flat as traders hedged their bets on the outlook for interest rates. Gilead Sciences ticked down even after it won Food and Drug Administration approval for a highly ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The Food and Drug Administration on Wednesday granted approval for Gilead Sciences’ twice-yearly injectable HIV prevention ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.